Literature DB >> 11376193

Progressive brain atrophy on serial MRI in dementia with Lewy bodies, AD, and vascular dementia.

J T O'Brien1, S Paling, R Barber, E D Williams, C Ballard, I G McKeith, A Gholkar, W R Crum, M N Rossor, N C Fox.   

Abstract

The authors determined rates of brain atrophy, as assessed by the boundary shift integral on serial MRI, in patients with dementia with Lewy Bodies (DLB, n = 10), AD (n = 9), vascular dementia (VaD, n = 9), and age-matched controls (n = 20). Mean % +/- SD atrophy rates per year were as follows: DLB, 1.4 +/- 1.1; AD, 2.0 +/- 0.9; VaD, 1.9 +/- 1.1; and controls, 0.5 +/- 0.7. Dementia subjects had higher rates than controls (p < 0.001), but there were no significant differences between the three dementia groups. The authors found accelerating atrophy with increasing severity of cognitive impairment, further emphasizing the need for early diagnosis and intervention in dementia.

Entities:  

Mesh:

Year:  2001        PMID: 11376193     DOI: 10.1212/wnl.56.10.1386

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  46 in total

1.  Global Cerebral Atrophy Detected by Routine Imaging: Relationship with Age, Hippocampal Atrophy, and White Matter Hyperintensities.

Authors:  Omar M Al-Janabi; Pradeep Panuganti; Erin L Abner; Ahmed A Bahrani; Ronan Murphy; Shoshana H Bardach; Allison Caban-Holt; Peter T Nelson; Brian T Gold; Charles D Smith; Donna M Wilcock; Gregory A Jicha
Journal:  J Neuroimaging       Date:  2018-01-05       Impact factor: 2.486

Review 2.  Neuroradiological findings in vascular dementia.

Authors:  Ali Guermazi; Yves Miaux; Alex Rovira-Cañellas; Joyce Suhy; Jon Pauls; Ria Lopez; Holly Posner
Journal:  Neuroradiology       Date:  2006-11-18       Impact factor: 2.804

3.  Combining short interval MRI in Alzheimer's disease: Implications for therapeutic trials.

Authors:  J M Schott; C Frost; J L Whitwell; D G Macmanus; R G Boyes; M N Rossor; N C Fox
Journal:  J Neurol       Date:  2006-09-22       Impact factor: 4.849

Review 4.  Brain mapping as a tool to study neurodegeneration.

Authors:  Liana G Apostolova; Paul M Thompson
Journal:  Neurotherapeutics       Date:  2007-07       Impact factor: 7.620

Review 5.  Use of biomarkers to select the target population for clinical trials in subjects with mild cognitive impairment.

Authors:  P J Visser
Journal:  J Nutr Health Aging       Date:  2009-04       Impact factor: 4.075

Review 6.  Progression of atrophy in Alzheimer's disease and related disorders.

Authors:  Jennifer L Whitwell
Journal:  Neurotox Res       Date:  2010-03-30       Impact factor: 3.911

7.  Responses of the Human Brain to Mild Dehydration and Rehydration Explored In Vivo by 1H-MR Imaging and Spectroscopy.

Authors:  A Biller; M Reuter; B Patenaude; G A Homola; F Breuer; M Bendszus; A J Bartsch
Journal:  AJNR Am J Neuroradiol       Date:  2015-09-17       Impact factor: 3.825

Review 8.  Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease. FDG-PET studies in MCI and AD.

Authors:  Lisa Mosconi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-04       Impact factor: 9.236

Review 9.  Dementia with Lewy bodies. Review of diagnosis and pharmacologic management.

Authors:  Christopher Frank
Journal:  Can Fam Physician       Date:  2003-10       Impact factor: 3.275

10.  Dynamics of gray matter loss in Alzheimer's disease.

Authors:  Paul M Thompson; Kiralee M Hayashi; Greig de Zubicaray; Andrew L Janke; Stephen E Rose; James Semple; David Herman; Michael S Hong; Stephanie S Dittmer; David M Doddrell; Arthur W Toga
Journal:  J Neurosci       Date:  2003-02-01       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.